| HOME >> BIOLOGY >> TECHNOLOGY |
ANTONY, France, July 10 /PRNewswire-FirstCall/ --
- 1st Half-Year Sales Up 16%
- Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal to)12%
EUR millions 2006 2007 07/06 2008 08/07
EURM %Sales EURM %Sales % EURM %Sales %
change change
Southern Europe (1) 20.5 72 23.2 72 13 26.8 71 15
Other EU countries (2) 6.9 24 7.7 24 11 9.3 24 20
Other markets 1.2 4 1.3 4 15 2.0 5 47
SLIT 21.8 76 25.1 77 15 30.4 80 21
SCIT 5.4 19 5.6 18 5 6.1 16 7
Other products 1.5 5 1.5 5 (0) 1.6 4 4
Total Q2 sales 28.6 100 32.2 100 13 38.0 100 18
Southern Europe (1) 48.1 75 56.5 76 18 64.7 75 14
Other EU countries (2) 13.7 21 15.8 21 15 18.6 21 18
Other markets 2.4 4 2.5 3 5 3.7 4 46
SLIT 49.4 77 59.7 80 21 71.3 82 19
SCIT 11.6 18 11.8 16 2 12.3 14 4
Other products 3.2 5 3.2 4 3 3.4 4 6
Total H1 sales 64.2 100 74.8 100 17 87.0 100 16
(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included
2008 second quarter sales recorded strong growth in all markets (+18% vs +13% in 2007). Eastern European markets and other markets outside Europe made a significant contribution to this growth. The most buoyant segment of the market remained desensitisation via the sublingual route (SLIT, +21%, vs +15% in 2007) whose reputation was enhanced by the launch of allergen tablets.
Cumulat
'/>"/>
| SOURCE Stallergenes Copyright©2008 PR Newswire. All rights reserved |